257 related articles for article (PubMed ID: 18829470)
1. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer.
Toschi L; Jänne PA
Clin Cancer Res; 2008 Oct; 14(19):5941-6. PubMed ID: 18829470
[TBL] [Abstract][Full Text] [Related]
2. Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4.
Matsumoto K; Nakamura T; Sakai K; Nakamura T
Proteomics; 2008 Aug; 8(16):3360-70. PubMed ID: 18646008
[TBL] [Abstract][Full Text] [Related]
3. Hepatocyte growth factor expression in human cancer and therapy with specific inhibitors.
Haddad R; Lipson KE; Webb CP
Anticancer Res; 2001; 21(6B):4243-52. PubMed ID: 11908677
[TBL] [Abstract][Full Text] [Related]
4. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
Eder JP; Vande Woude GF; Boerner SA; LoRusso PM
Clin Cancer Res; 2009 Apr; 15(7):2207-14. PubMed ID: 19318488
[TBL] [Abstract][Full Text] [Related]
5. Adenoviral-mediated gene transduction of the hepatocyte growth factor (HGF) antagonist, NK4, suppresses peritoneal metastases of gastric cancer in nude mice.
Ueda K; Iwahashi M; Matsuura I; Nakamori M; Nakamura M; Ojima T; Naka T; Ishida K; Matsumoto K; Nakamura T; Yamaue H
Eur J Cancer; 2004 Sep; 40(14):2135-42. PubMed ID: 15341989
[TBL] [Abstract][Full Text] [Related]
6. Noncompetitive inhibition of hepatocyte growth factor-dependent Met signaling by a phage-derived peptide.
Tam EM; Runyon ST; Santell L; Quan C; Yao X; Kirchhofer D; Skelton NJ; Lazarus RA
J Mol Biol; 2009 Jan; 385(1):79-90. PubMed ID: 18973760
[TBL] [Abstract][Full Text] [Related]
7. Molecular cancer therapy: can our expectation be MET?
Migliore C; Giordano S
Eur J Cancer; 2008 Mar; 44(5):641-51. PubMed ID: 18295476
[TBL] [Abstract][Full Text] [Related]
8. Rilotumumab, a mAb against human hepatocyte growth factor for the treatment of cancer.
Giordano S
Curr Opin Mol Ther; 2009 Aug; 11(4):448-55. PubMed ID: 19649990
[TBL] [Abstract][Full Text] [Related]
9. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.
Abdollahi A; Folkman J
Drug Resist Updat; 2010; 13(1-2):16-28. PubMed ID: 20061178
[TBL] [Abstract][Full Text] [Related]
10. Novel agents on the horizon for cancer therapy.
Ma WW; Adjei AA
CA Cancer J Clin; 2009; 59(2):111-37. PubMed ID: 19278961
[TBL] [Abstract][Full Text] [Related]
11. CHM-1 inhibits hepatocyte growth factor-induced invasion of SK-Hep-1 human hepatocellular carcinoma cells by suppressing matrix metalloproteinase-9 expression.
Wang SW; Pan SL; Peng CY; Huang DY; Tsai AC; Chang YL; Guh JH; Kuo SC; Lee KH; Teng CM
Cancer Lett; 2007 Nov; 257(1):87-96. PubMed ID: 17689859
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms and significance of bifunctional NK4 in cancer treatment.
Matsumoto K; Nakamura T
Biochem Biophys Res Commun; 2005 Jul; 333(2):316-27. PubMed ID: 15950947
[TBL] [Abstract][Full Text] [Related]
13. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges.
Liu X; Newton RC; Scherle PA
Trends Mol Med; 2010 Jan; 16(1):37-45. PubMed ID: 20031486
[TBL] [Abstract][Full Text] [Related]
14. A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway.
Tiran Z; Oren A; Hermesh C; Rotman G; Levine Z; Amitai H; Handelsman T; Beiman M; Chen A; Landesman-Milo D; Dassa L; Peres Y; Koifman C; Glezer S; Vidal-Finkelstein R; Bahat K; Pergam T; Israel C; Horev J; Tsarfaty I; Ayalon-Soffer M
Clin Cancer Res; 2008 Jul; 14(14):4612-21. PubMed ID: 18628476
[TBL] [Abstract][Full Text] [Related]
15. Drug development of MET inhibitors: targeting oncogene addiction and expedience.
Comoglio PM; Giordano S; Trusolino L
Nat Rev Drug Discov; 2008 Jun; 7(6):504-16. PubMed ID: 18511928
[TBL] [Abstract][Full Text] [Related]
16. The emerging role of MET/HGF inhibitors in oncology.
Scagliotti GV; Novello S; von Pawel J
Cancer Treat Rev; 2013 Nov; 39(7):793-801. PubMed ID: 23453860
[TBL] [Abstract][Full Text] [Related]
17. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
Tortora G; Ciardiello F; Gasparini G
Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
[TBL] [Abstract][Full Text] [Related]
18. Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist.
Kirchhofer D; Lipari MT; Santell L; Billeci KL; Maun HR; Sandoval WN; Moran P; Ridgway J; Eigenbrot C; Lazarus RA
Proc Natl Acad Sci U S A; 2007 Mar; 104(13):5306-11. PubMed ID: 17372204
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
[TBL] [Abstract][Full Text] [Related]
20. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
Chen FL; Xia W; Spector NL
Clin Cancer Res; 2008 Nov; 14(21):6730-4. PubMed ID: 18980964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
